News from amarantus biosciences, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

( Bloomberg:AMBS@US,RICS:AMBS,ISIN:US02300U1060,OTC-BB:AMBS,OTC-QB:AMBS,OtherOTC:AMBS)

Feb 09, 2016, 14:23 ET

Amarantus to Present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference

Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and...

Feb 05, 2016, 08:30 ET

Amarantus Requests Rare Pediatric Disease Designation from US FDA for MANF in the Treatment of Retinitis Pigmentosa

Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and...

Feb 03, 2016, 09:00 ET

Amarantus Receives Dual Notices of Allowance from European Patent Office for Engineered Skin Substitute (ESS)

Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and...

Jan 29, 2016, 09:00 ET

Amarantus Announces Issuance of Chinese Patent Covering Use of MANF for the Treatment of Parkinson's Disease

Amarantus Bioscience Holdings, Inc. (OTCQX: AMBS), a biotechnology company developing products in Regenerative Medicine, Neurology and Orphan...

Jan 27, 2016, 15:30 ET

Amarantus Announces $1M Investment

Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing products in Regenerative Medicine, Neurology and Orphan...

Jan 19, 2016, 09:15 ET

Amarantus Enters Into Letter of Intent to Merge Diagnostics Business Unit Into Avant Diagnostics

Amarantus Bioscience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing products in Regenerative Medicine, Neurology and Orphan...

Jan 15, 2016, 08:00 ET

Amarantus to Present at ICV Sonoma Event

Amarantus Bioscience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapies in Regenerative Medicine and Orphan disease, today...

Jan 11, 2016, 09:00 ET

Amarantus to Present at SeeThruEquity First Annual Microcap Healthcare Investor Conference

Amarantus Bioscience Holdings, Inc. (OTCQX: AMBS), a biotechnology company developing therapies in Regenerative Medicine and Orphan diseases,...

Dec 29, 2015, 08:00 ET

Amarantus Requests Rare Pediatric Disease and Orphan Drug Designations from US FDA for Engineered Skin Substitute in the Treatment of Giant Congenital Melanocytic Nevi

Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and...

Dec 22, 2015, 10:41 ET
Image of an ESS skin graft produced from initial engineering run completed in December 2015 (#2 above)

Amarantus Provides Update on cGMP Manufacturing Validation for the Engineered Skin Substitute (ESS) Program

Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology...

Dec 16, 2015, 10:56 ET

Amarantus Announces Peer-Reviewed Publication Further Describing Mechanisms of Action for Eltoprazine in the Treatment of Parkinson's LID

Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and...

Dec 15, 2015, 07:30 ET

Amarantus Receives Notice of Allowance for U.S. Patent Application Covering Method of Treating Parkinson's Disease Levodopa-induced Dyskinesia (PD-LID)

  Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine,...

Dec 10, 2015, 10:48 ET

Amarantus Retains WallachBeth Capital to Evaluate Strategic Options for MANF Gene Therapy Program

Amarantus BioScience Holdings, Inc. (OTCQX: AMBS), a biotechnology company developing product candidates in Regenerative Medicine and Orphan...

Dec 08, 2015, 08:06 ET

Amarantus Announces Positive Phase 2 Data for Eltoprazine in Alzheimer's Aggression

Amarantus Bioscience Holdings, Inc. (OTCQX: AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in neurology...

Dec 07, 2015, 08:30 ET

Amarantus to Present at ICV Manhattan Event on December 8, 2015

Amarantus Bioscience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapies in Regenerative Medicine and Orphan diseases, today...

Dec 03, 2015, 08:00 ET

Amarantus to Present at LD Micro Main Event on December 3, 2015

Amarantus Bioscience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan...

Sep 30, 2015, 16:29 ET
View investor presentations 24/7 at www.virtualinvestorconferences.com.

Amarantus Announces an Interactive Live Webcast Presentation at VirtualInvestorConferences.com on October 1, 2015

- Individual and institutional investors as well as advisors are invited to attend the real-time virtual event on Oct. 1 at 11:30 a.m. EDT -...

Feb 04, 2014, 08:30 ET

Amarantus Announces Positive Phase 2a Data for Eltoprazine in Adult ADHD

 - 36 out of 47 adult subjects (77%) completed the double-blind placebo controlled, multiple dose, crossover study - Primary...

Feb 28, 2013, 08:00 ET

Amarantus BioScience to Present MANF Parkinson's Data at the 15th Annual American Society for Experimental NeuroTherapeutics

 Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases...

Feb 25, 2013, 10:32 ET

Amarantus BioScience and Banyan Biomarkers to Present Poster of MANF Data at The 3rd Annual Traumatic Brain Injury Conference

 Amarantus BioScience, Inc. (OTCQB:AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated...